Sandoz’ Loryna Strategy Validated; Bayer’s Yaz Patent Struck Down A Year Before Expiration
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis is relaunching its version of the oral contraceptive after the Federal Circuit reverses a lower court and finds Bayer’s patent is invalid due to obviousness; the appeals court also finds that Biogen Idec’s Rituxan patent does not block GSK’s Arzerra.
You may also be interested in...
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
US FDA To Lose Another COVID-19 Response Leader With Anand Shah’s Resignation
Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: